-101 suppresses the development of MLL-rearranged acute myeloid leukemia. Haematologica. 2019; 104:xxx doi:10.3324/haematol.2018.209437 Publisher's Disclaimer. We used miR-150 as a control because, despite not being in the network, its expression is downregulated in both AML and CML. (Figure 1E-F; Supplementary Figure S2D ).
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Dysregulation of miRNAs (a class of short noncoding RNAs) has been observed in solid tumors and leukemia, 1, 2 and the role of miRNAs in cancer development is largely context-dependent. 2 While several miRNAs (e.g., miR-29b) 3 have been functionally linked to acute myeloid leukemia (AML), their antitumor effects in vivo are not evident, possibly due to the complexity and diversity of miRNA-mediated gene regulation. It remains unclear how miRNAs contribute to an aggressive phenotype in heterogenous AML. Using an integrated miRNA and mRNA expression analysis, here
we uncover a miRNA-regulatory network composed of eight miRNAs (i.e., miR-29a/b, miR-101, miR-222, miR-26b, miR-27b, miR-140 and miR-155) whose downregulation is associated with leukemia aggressiveness. We also define a tumor suppressive role for miR-101 in the development Aberrant overexpression of HOXA9 and MEIS1 is required for the induction and maintenance of MLL-rearranged AML, where LSCs have been functionally defined. 4, 5 We and others have shown that MLL fusion proteins (e.g., MLL-AF9) can serve as an initiating event for oncogenic conversion of normal HSPCs into pre-LSCs, which subsequently acquire additional events upon transplantation into mice for the development of LSCs. [4] [5] [6] [7] The self-renewal 3 rate in a pre-leukemic clone determines subsequent tumorigenic potential in vivo. We have previously demonstrated that pre-LSCs transformed from normal HSPCs by MLL-AF9 have higher self-renewal potential and produce a more aggressive leukemia in mice with shorter latency than pre-LSCs transformed by HOXA9/MEIS1. 5, 7 Despite major differences in self-renewal and mouse survival, pre-LSCs mediated by MLL-AF9 and HOXA9/MEIS1 display similar immunophenotype and induce AML with similar histopathologic manifestations. 5, 7 Thus, genes differentially expressed in MLL-AF9 versus HOXA9/MEIS1 pre-LSCs may contribute to the highly aggressive phenotype in MLL-AF9-induced AML.
To identify miRNAs that regulate the differential gene expression, we performed an integrated analysis for miRNA and mRNA expression profiling using the Bayesian Network with SplittingAveraging strategy, 8 and identified a tumor suppressive miRNA-regulatory network in HSPC- Among the eight miRNAs, miR-29b has been functionally defined as a tumor suppressor and its overexpression reduced tumorigenicity in a BCR-ABL-expressed K562 xenograft mouse model of human chronic myeloid leukemia (CML) by targeting apoptosis, cell cycle and proliferation pathways. 3 While miR-101 is reported as a putative tumor suppressor in several types of cancer via 4 targeting diverse oncogenic pathways, 10 its role in AML has not yet been explored. To further evaluate the miRNA-regulatory network, we investigated the tumor suppressive function of miR-101, which was one of the most downregulated miRNAs identified, in MLL-AF9-induced AML.
We used miR-150 as a control because, despite not being in the network, its expression is downregulated in both AML and CML. These findings suggest that restoring expression of miR-101 impairs pre-LSC functions through regulation of genes associated with Wnt/self-renewal, pro-survival and cell cycle pathways.
5
We next assessed the inhibitory effect of miR-101 overexpression on AML development by intravenously transplanting miR-101-expressing MLL-AF9 pre-LSCs into sublethally irradiated syngeneic recipient mice. Our data showed that enforced expression of miR-101 reduced the incidence and delayed the onset and progression of AML in mice, which was accompanied by a significant decrease in leukemic cell infiltration in bone marrow (BM, Figure 2A-B) . miR-101-expressing MLL-AF9 LSCs flow-sorted from primary AML revealed reduced colony-forming capacity ( Figure 2C; Supplementary Figure S3 ). This was likely caused by miR-101-induced suppression of Wnt target genes (Tcf7l2 and c-Fos), and cell cycle arrest at the G1 phase via upregulation of p21, p27 and Gadd45a ( Figure 2D) . As a consequence of compromised LSCs, miR-101-expressing AML cells from primary recipients generated a less aggressive leukemia in secondary recipient mice, whose BM cells exhibited a marked decrease in nuclear active β -catenin ( Figure 2E ). Altogether, these data underscore a tumor suppressor role for miR-101, whose ectopic expression impairs LSC development and reduces AML aggressiveness in mice.
We then investigated the effect of miR-101 overexpression on tumor burden in a mouse xenograft model of human MLL-AF9 (MOLM-13) AML, which has an extremely short latency (14 days) and Results were normalized using snoRNA202 as control. Error bars are shown as mean ± SEM of three independent experiments unless specified otherwise. *, P < 0.05; **, P < 0.01; ***, P < 0.0005; ****, P < 0.0001. RT-qPCR analysis of miRNA expression alteration in response to a selective EZH2 inhibitor, EPZ-6438, in human MOLM-13 cells. **, P < 0.01; ***, P < 0.0005; NS, not significant (P > 0.05).
Methods

Mice
Six-to 8-week-old C57BL/6 (BL6) and NSG female mice were obtained from Australian BioResources, Mossvale, NSW, Australia. All animal experiments were approved by the Animal Ethics Committee of the University of New South Wales, Sydney, NSW, Australia.
Retroviral constructs and viral transfection
Murine stem cell virus (MSCV)-based retroviral vectors carrying expression cassettes containing HOXA9, MEIS1 and MLL-AF9 have been described in our previous studies. [1] [2] [3] The retroviral MSCVmiR-101-puro, MSCV-miR-29b-puro and MSCV-miR-150-puro expression vectors were generated by GenScript (NJ, USA). pLX304-FOS-V5 was a gift from William Hahn (Addgene plasmid 59140) 4 and pLX304 was a gift from David Root (Addgene plasmid 25890).
5 Viral stocks were produced from 293T cells by transient transfection using Lipofectamine 2000. Virus-containing supernatants were harvested 48-72 hours post-transfection, filtered through 0.45-µm membrane, and concentrated by centrifugation.
Hematopoietic cell isolation, transduction and transplantation HSPC-enriched LSK cells (Lin
- CD127 -
Sca1
+ c-Kit + , BioLegend, Balcatta, WA, Australia) were flowsorted from mouse BM as previously described. 1, 2, 6 To generate pre-LSCs, 3-5x10 4 HSPCs were incubated with concentrated virus carrying MLL-AF9 or HOXA9/MEIS1 supplemented with 7.5 µg/ml polybrene (Sigma-Aldrich, Castle Hill, NSW, Australia). Two rounds of transduction were performed for each experiment. For mouse bone marrow transplantation, 1x10 6 GFP + pre-LSCs or 1x10 5 GFP + leukemic cells flow-sorted from primary AML mice were injected intravenously by the tail vein into sublethally irradiated (6 Gy) BL6 syngeneic recipient mice as previously described.
1-3
Fluorescence-activated cell sorting (FACS) Alexa Fluor 647 anti-human CD45 antibodies were purchased from BioLegend (304018). Cells were stained with antibodies at 4 °C for 20 min before being subjected to FACS analysis using a BD LSRFortessa™ cell analyzer (BD Biosciences, North Ryde, NSW, Australia). Cell sorting was conducted using a BD Influx™ high-speed cell sorter (BD Biosciences). Flow cytometry data were analyzed using FlowJo software (TreeStar, Ashland, OR, USA).
In vitro cell cycle and apoptosis
For cell cycle analysis, cells were fixed in ice-cold 70% ethanol for 2 hours at -20 °C, stained with anti-Ki67-Alexa Fluor 647 (BD Biosciences) and 7-amino-actinomycin D (7AAD, BD Biosciences) in staining solution (50 µg/ml propidium iodide, 0.1% Triton X-100 and 100 µg/ml DNase-free RNaseA) and incubated for 20 min at 4 °C prior to flow cytometric analysis. For apoptosis analysis, cells were incubated with Annexin V-APC staining solution (BD Biosciences, 550474) at room temperature for 10 minutes, followed by staining with 7-Aminoactinomycin D (7-AAD) (BD Biosciences, 559925) for 15 min on ice and subsequent analysis by flow cytometry.
miRNA and mRNA gene expression profiling Total mRNA was extracted using the RNeasy mini kit (Qiagen, Hilden, Germany, 74106) and miRNA was extracted using the miRNeasy mini kit (Qiagen, 217004). The array data are available in ArrayExpress under the accession numbers E-MTAB-7344, E-MTAB-7355 and E-MTAB-7356.
Labelling, hybridization and scanning were performed by the Ramaciotti Centre for Gene Function Analysis (University of New South Wales, Sydney, Australia), with mRNA hybridized to Illumina murine WG-6 v2.0 expression array for mRNA expression profiling and miRNA hybridized to Exiqon miRCURY LNA microRNA Array for global microRNA expression profiling. The mRNA expression profiling was analyzed using the GenePattern software (Broad Institute, MIT) as previously described.
2
Bayesian Networks with Splitting-Averaging strategy used to identify miRNA-mRNA network A method called Bayesian network with splitting-averaging (BNSA) was used to identify complex miRNA-mRNA interactions for functional miRNA-mRNA regulatory networks (FMRMs). This method integrates miRNA-target information, sample-matched expression profiles of miRNA and mRNA, and sample categories. In order to capture all possible interactions, this method groups expression profiles of miRNAs and mRNAs together according to their sample category and then learns Bayesian Network (BN) structures on the relative expression changes of miRNA and mRNA in each category, respectively. The miRNA-target information acts as a constraint to guide the structure learning, whereby the miRNAs represent the parent nodes while the mRNAs are the descendant nodes. The edges linking the parent nodes to descendant nodes can only be those defined in the miRNA-target predictions. Interaction networks learned on each category are then integrated by BN averaging procedure. To avoid statistically insignificant results due to the small size of data sets, it uses bootstrapping to achieve reliable inference and integration. Cell viability assay Cell viability was measured by the AlamarBlue TM cell viability assay (Thermo Fisher Scientific, North Ryde, NSW, Australia, DAL1025) as per manufacturer's instruction. Briefly, 5x10
3 human MOLM-13 cells were seeded in 96-well plates with 180 µL media per well. After 48 hours 20 µL of AlamarBlue reagent was added into each well and incubated at 37°C for 6 hours before absorbance values were measured at 570 and 595 nm using the Benchmark Plus microplate reader (Bio-Rad, Gladeville, NSW, Australia).
Colony formation assay
Cells were seeded at a density of 1x10 3 cells in 35 mm dishes in methylcellulose supplemented with mIL-3. Colonies were counted after 5 days incubation at 37°C. For serial replating assay, colonies were harvested, and 1x10 3 cells were subsequently replated in fresh methylcellulose. Six rounds of serial replating were performed.
Real-time quantitative qPCR analysis (RT-qPCR) for gene expression
Total RNA was extracted from cells using the RNeasy mini kit (Qiagen, 74106). cDNA was synthesized from total RNA using random primers (Thermo Fisher Scientific, 48190011) and M-MLV Reverse Transcriptase (Thermo Fisher Scientific, 28025013). RT-qPCR was performed using the Power SYBR® Green PCR Master Mix (Thermo Fisher Scientific, 436708) or SsoAdvanced Universal SYBR Green Supermix (Bio-Rad).
The values for target gene expression were normalized against the house-keeping gene Gapdh. RTqPCR primers include mouse Bcl11a: forward 5'-GCGACACTTGTCCTTCACACACC-3', reverse 5'-GCTTCCATCCGAAAACTGCCACAC-3'; Mouse Meis2: forward 5'-GCAATCTATGGGCAC CCGTTGT-3', reverse 5'-CGGCGCGAACCTGCTTG-3'; mouse Six1: forward 5'-CAAGGAAAG Confocal immunofluorescence 4 x 10 4 cells were cytospun onto glass slides, fixed in 4% paraformaldehyde in PBS for 10 minutes at room temperature and then washed three times for 5 minutes in PBS with 0.1% Tween-20 (PBS-T). Non-specific antibody binding was blocked with blocking media (10% goat serum and 2% BSA in PBS-T) for 1 hour. Slides were stained overnight at 4C with a mouse monoclonal antibody against non-phospho (active) β-catenin (Ser33/Ser37/Thr41; clone 8E7, Merck, Bayswater, VIC, Australia, 05-665) at a dilution of 1:100, washed three times for 5 minutes in PBS-T, and then stained for 1 hour with Alexa Fluor 568-conjugated donkey anti-mouse secondary antibody (Abcam, ab175472) at a dilution of 1:500 and washed three times with PBS-T for 5 minutes followed by staining with DAPI (1:4000, Thermo Fisher Scientific) for 30 minutes. Coverslips were mounted with ProLong Gold antifade mountant (Thermo Fisher Scientific) and edges were sealed with nail polish to prevent desiccation. Immunofluorescence images were taken with a TCS SP5 MP-STED confocal microscope (Leica Microsystems, Mannheim, Germany) and processed using NIH ImageJ software.
In vivo bioluminescence imaging of NSG mice GFP-luciferase-expressing human MOLM-13 AML cells were generated by transducing retroviral vector SFG-NES-TGL (GFP-FLuc; a gift from Vladimir Ponomarev) 8 into MOLM-13 cells (ATCC, Noble Park North, VIC, Australia; recently authenticated by Short Tandem Repeat PCR and tested for mycoplasma contamination) followed by flow-sorting of GFP + transduced cells. 5 x 10 5 transduced cells were injected intravenously by the tail vein into NSG mice, which were monitored for assessing in vivo engraftment of human AML cells using non-invasive bioluminescent imaging. Images were taken 10 min after intraperitoneal injection of D-luciferin (150 mg/kg of body weight; Promega, P1043) for FLuc signals detected by the IVIS Spectrum CT (Caliper Life Sciences, MA, USA). 8, 9 Signal intensity quantification and analysis were performed using the Living Image 4.5.5 software (Perkin Elmer, Waltham, MA, USA). The bioluminescent signal was recorded as radiance photons/sec/cm 2 /steradian (p/s/cm 2 ), represented in pseudocolor to indicate the signal intensities.
Luciferase Reporter Assay
For transfection, 6x10 3 293T cells/well were plated in 96-well plates in triplicate for each condition. After incubation overnight, cells were transfected with 20 ng of the pMIR-REPORT plasmid (pMIR-REPORT miRNA expression vector system; Thermo Fisher Scientific, AM5795) bearing the 3'UTR of c-FOS, and 20 ng of MSCV-miR-101-puro or MSCV-miR-150-puro versus control empty vector (EV) using Lipofectamine 3000 (Thermo Fisher Scientific, L3000015). pMIR-REPORT™ Betagalactosidase Reporter Control Vector (Thermo Fisher Scientific, AM5795) (1 ng) was cotransfected for transfection efficiency control in all transfections. Transduced cells were lysed, and firefly luciferase and β-galactosidase activities were detected using Dual-Light® Luciferase & β-Galactosidase Reporter Gene Assay System (Thermo Fisher Scientific, T1003/T1004) 48h posttransfection following the manufacturer's protocol. Firefly luciferase activity was normalized to β-galactosidase activity for each transfected well. Each experiment was performed in triplicate and repeated three times.
Statistical analysis
Statistical significance of differences was determined by an unpaired two-tailed Student's t-test for comparison between two groups and log-rank test for Kaplan-Meier survival curves using GraphPad Prism 7 (La Jolla, CA, USA). Data are presented as mean ± SEM. *P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.0001, NS = Not Significant.
